<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04844840</url>
  </required_header>
  <id_info>
    <org_study_id>SRN-705-007</org_study_id>
    <nct_id>NCT04844840</nct_id>
  </id_info>
  <brief_title>A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence</brief_title>
  <official_title>A Phase 2, Multi-Center, Randomized, Double-Blind, Multiple Arm, Controlled Pilot Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Reducing Post- Keloidectomy Keloid Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sirnaomics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sirnaomics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2, randomized, double-blind, multiple arm, controlled study to evaluate safety &amp;&#xD;
      efficacy of various doses of STP705 in reducing post Keloidectomy keloid recurrence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study isto assess the safety, tolerability, and efficacy of various&#xD;
      doses of STP705 and placebo via intradermal injection into the keloid excision site, to&#xD;
      prevent the recurrence of keloids following their excision.&#xD;
&#xD;
      A total of up to 60 adult subjects will be treated once weekly for 4 weeks. One eligible&#xD;
      qualifying keloid will be excised. The subjects will be randomized to receive STP705, placebo&#xD;
      or SOC alone (no injection for treatment of the keloidectomy excision suture line.&#xD;
&#xD;
      To be eligible, keloid scar(s) must have been present for at least one year with a target&#xD;
      keloid area on the trunk or extremity (non-peri-orbital/-anogenital/-scalp), measures&#xD;
      ≥0.30cm2, and be suitable for surgical excision which will result in a single wound no&#xD;
      greater than 7cm long.&#xD;
&#xD;
      The study is divided into 3 phase: screening phase (4 weeks), Treatment phase (up to 4 weeks&#xD;
      +/- allowed windows), Follow up phase (up to 52 weeks +/- allowed windows).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>10 subjects each will be randomly allocated to either the assigned STP705 treatment group, placebo or SOC alone in a 1:1:1:1:1:1 ratio.&#xD;
An individual, independent of the clinical trial team, will develop the randomization schedules. The actual randomization assignment will be prepared through a web-based system. STP705 or placebo will be injected intradermally at the keloid excision site.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This is a double-blind study. All subjects, investigator, and site staff (except unblinded pharmacist or designated site staff) in the study will be blinded to the treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Recurrence</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of recurrence in subjects undergone surgery alone (with or without placebo) vs surgery and STP705</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Keloid volume/size</measure>
    <time_frame>12 months</time_frame>
    <description>Change in size of post excision keloid from baseline by volumetric measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Keloid size</measure>
    <time_frame>12 months</time_frame>
    <description>Change of Keloid scar appearance from baseline evaluated by caliper</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Keloid scar appearance</measure>
    <time_frame>12 months</time_frame>
    <description>Change of Keloid scar appearance from baseline evaluated by POSAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DLQI</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VSS score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Keloid</condition>
  <arm_group>
    <arm_group_label>Cohort 1: STP705 10 μg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STP705 at the assigned dose will be injected intradermal into the excised keloid site once weekly for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: STP705 20 μg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STP705 at the assigned dose will be injected intradermal into the excised keloid site once weekly for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: STP705 30 μg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STP705 at the assigned dose will be injected intradermal into the excised keloid site once weekly for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: STP705 40 μg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STP705 at the assigned dose will be injected intradermal into the excised keloid site once weekly for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (saline) will be injected intradermal into the excised keloid site once weekly for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: SOC alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>SOC (no injection)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STP705</intervention_name>
    <description>STP705 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA, respectively</description>
    <arm_group_label>Cohort 1: STP705 10 μg dose</arm_group_label>
    <arm_group_label>Cohort 2: STP705 20 μg dose</arm_group_label>
    <arm_group_label>Cohort 3: STP705 30 μg dose</arm_group_label>
    <arm_group_label>Cohort 4: STP705 40 μg dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Cohort 5: Placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female ≥18 years of age, inclusive having at least one keloid scar.&#xD;
&#xD;
          2. Female subjects of child-bearing potential must agree to the use of an effective&#xD;
             method(s) of contraception beginning at or before the screening visit until one month&#xD;
             after administration of the final study dose. For the purposes of the protocol, highly&#xD;
             effective method(s) of contraception will be defined as consistently and correctly&#xD;
             used implants, injectables, combined oral contraceptives, sexual abstinence or a&#xD;
             vasectomized partner.&#xD;
&#xD;
          3. The keloid scar(s) must have been present for at least one year with a target keloid&#xD;
             area on the trunk or extremity (non-peri-orbital/-anogenital/-facial/-scalp), measures&#xD;
             ≥0.30cm2, and be suitable for surgical excision which will result in a single wound no&#xD;
             greater than 7cm long.&#xD;
&#xD;
          4. Able and willing to give written informed consent.&#xD;
&#xD;
          5. Willing to comply with the follow up schedule for 12 months.&#xD;
&#xD;
          6. Medically healthy with no clinically significant medical history, physical&#xD;
             examination, laboratory profiles, or vital sign abnormalities as deemed by the PI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment of the keloid scar in the previous 6 weeks.&#xD;
&#xD;
          2. The keloid scar must not have undergone prior surgical excisions (laser, cryotherapy&#xD;
             or surgery).&#xD;
&#xD;
          3. The keloid scar must not have undergone prior radiation treatment.&#xD;
&#xD;
          4. Pregnant, lactating, or planning to become pregnant during the course of the study.&#xD;
&#xD;
          5. Advanced or poorly controlled diabetes.&#xD;
&#xD;
          6. Active local infection at the treatment site and/or systemic infection that would in&#xD;
             the opinion of the Investigator affect the treatment site.&#xD;
&#xD;
          7. Any medical or surgical condition that will interfere with required study activities&#xD;
             or assessments or that make the study treatments contraindicated in the opinion of the&#xD;
             study Investigator.&#xD;
&#xD;
          8. Unwilling to refrain from use of any other scar treatment therapy/scar improving&#xD;
             product, during the study.&#xD;
&#xD;
          9. Regular, continuous use of systemic corticosteroid therapy or topical corticosteroid&#xD;
             use in the area to be treated.&#xD;
&#xD;
         10. Current participation or participation within the last 1 months in the study of an&#xD;
             investigational drug, device, or biologic.&#xD;
&#xD;
         11. Unable or unwilling to follow post-operative instructions.&#xD;
&#xD;
         12. Mentally or legally incapacitated or has significant emotional problems at the time of&#xD;
             screening visit or expected during the conduct of the study.&#xD;
&#xD;
         13. History or presence of hypersensitivity or idiosyncratic reaction to the study drug or&#xD;
             related compounds, or drug product excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadia Sheibani</last_name>
    <role>Study Director</role>
    <affiliation>Director, Clinical Operations</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>nadia sheibani</last_name>
    <phone>301-740-1730</phone>
    <email>nadiasheibani@sirnaomics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MD Investigate</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MD Investigate</last_name>
      <phone>480-440-5985</phone>
    </contact>
    <investigator>
      <last_name>Brenda La Towsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Clinical and Cosmetic Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-933-6716</phone>
    </contact>
    <investigator>
      <last_name>Mark Nestor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schweiger Dermatology</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Schweiger Dermatology</last_name>
      <phone>609-219-5621</phone>
    </contact>
    <investigator>
      <last_name>David Goldberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keloid</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

